EGFR and cancer: Nine different drugs that are currently approved for cancer applications with reported angiostatic activity were obtained and analyzed (Table 1); it should be noted that EGFR antagonists and Torisel® also have other mechanisms of action to prevent cancer growth beyond angiostasis.